CTRI/2024/03/064100招募中4 期
A multicentric, open label study to evaluate the safety and efficacy of fixed-dose combination of Efonidipine 40 mg and Telmisartan 40 mg tablets in the management of Stage II hypertension. - NI
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adults with age 18 years and above 2. Patients diagnosed with Stage II hypertension (SBP/DBP: 160/100 mmHg or above) 3. Naïve patients or patients able to switch from their current antihypertensive therapy without any risk to the patient on the investigator opinion 4. Patients willing to sign informed consent.
排除标准
- •1. Patients with known hypersensitivity to angiotensin II receptor blockers or dihydropyridine calcium channel blockers
- •2. Patients with history of severe, malignant or secondary hypertension
- •3. Patient with cerebrovascular disease in the previous 3 months
- •4. Patients with chronic arrhythmia, sick sinus syndrome or sinus bradycardia (less than 50 beats per min)
- •5. Patients with second or third degree atrioventricular block
- •6. Female patients who are pregnant, lactating
研究者
相似试验
进行中（未招募）
1 期
To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH.MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2018-002796-18-PTBial - Portela & Ca, S.A.40
进行中（未招募）
1 期
To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH.Pulmonary arterial hypertensionEUCTR2018-002796-18-ITBIAL-Portela & Ca, S.A.40
进行中（未招募）
1 期
To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH.Pulmonary arterial hypertensionEUCTR2018-002796-18-ESBial - Portela & Ca, S.A.40
进行中（未招募）
1 期
To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH.Pulmonary arterial hypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-002796-18-ATBial - Portela & Ca, S.A.40
进行中（未招募）
1 期
To study the safety and how effective Long-term Zamicastat treatment is for Pulmonary Arterial HypertensioPulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-002796-18-GBBial - Portela & Ca, S.A32